ID: ALA4878541

Max Phase: Preclinical

Molecular Formula: C23H30N6O

Molecular Weight: 406.53

Molecule Type: Unknown

Representations

Canonical SMILES:  Cc1cncc(-c2cnc(NC3CCN(CCCN)CC3)c3[nH]c(=O)c(C)cc23)c1

Standard InChI:  InChI=1S/C23H30N6O/c1-15-10-17(13-25-12-15)20-14-26-22(21-19(20)11-16(2)23(30)28-21)27-18-4-8-29(9-5-18)7-3-6-24/h10-14,18H,3-9,24H2,1-2H3,(H,26,27)(H,28,30)

Standard InChI Key:  YKDUUWMPYBJPOG-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 406.53

Molecular Weight (Monoisotopic): 406.2481

AlogP: 2.83

#Rotatable Bonds: 6

Polar Surface Area: 99.93

Molecular Species: BASE

HBA: 6

HBD: 3

#RO5 Violations: 0

HBA (Lipinski): 7

HBD (Lipinski): 4

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 12.92

CX Basic pKa: 9.91

CX LogP: 1.08

CX LogD: -1.81

Aromatic Rings: 3

Heavy Atoms: 30

QED Weighted: 0.58

Np Likeness Score: -0.95

References

1. Clegg MA, Theodoulou NH, Bamborough P, Chung CW, Craggs PD, Demont EH, Gordon LJ, Liwicki GM, Phillipou A, Tomkinson NCO, Prinjha RK, Humphreys PG..  (2021)  Optimization of Naphthyridones into Selective TATA-Binding Protein Associated Factor 1 (TAF1) Bromodomain Inhibitors.,  12  (8.0): [PMID:34413961] [10.1021/acsmedchemlett.1c00294]

Source

Source(1):

• Scientific Literature